References
- Kane JM, Eerdekens M, Lindenmayer JP, Keith S, Lesen M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical anti-psychotic. Am J Psychiatry 2003;160:1125–32.
- Lasser R, Bossie G, Gharabawi G, Baldessarini R. Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone; a 12 month open trial. Int J Neuropsychopharmacol 2005;8:1–12.
- Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, . The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003;29;15–31.
- Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IPM, . Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008; 371:1085–97.
- Nasrallah HA. The case for long acting antipsychotic agents in the post-CATIE era. Acta Pasychiatr Scand 2007;115:260–7.
- Glazer WM, Kane JM. Depot neuroleptic therapy: an underutilized treatment option. J Clin Psychiatry 1992;53:426–33.
- Davis JM, Watanabe MD, Blake L. Depot antipsychotic drugs. Place in therapy. Drugs 1994;47:741–73.
- Patel MX, Nikolau V, David AS. Psychiatrists’ attitudes to maintenance medication for patients with schizophrenia. Psychol Med 2003;33:83–9.
- Patel M, Nikolou V, David S. Eliciting psychiatrists beliefs about side effects of typical and atypical antipsychotic drugs. Int J Psychiatry Clin Pract 2003;7:117–20.
- Miles SW, Davies K. What do practicing clinicians really think; a qualitative research exploration of RLAI use. Paper presented at RANZCP Meeting, Napier, New Zealand, 2007.
- Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol 2006;3:77–101.
- Aronson J. A pragmatic view of thematic analysis. The qualitative report 1994:2(1). http://www.nova.edu/ssss/QR/BackIssues/QR2-1
- Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261–76.
- Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962;10:799–812.
- Wing JK, Beevor AS, Curtis RH, Park RH, Hadden S, Burns A, . Health of the Nation outcome scale (HoNOS). Research and development. Br J Psychiatry 1998;172:11–18.
- Robert LW, Geppert CM. Ethical use of longacting medications in the treatment of severe and persistent mental illness. Compr Psychiatry 2004;45:161–7.
- Patel MX, David AS. Why aren't depot antipsychotics prescribed more often and what can be done about it? Adv Psychiatr Treat 2005;11:203–13.
- Patel MX, Haddad PM, Chaudhey IB, McLouglin S, Husain N, David AS. Psychiatrists’ use, knowledge and attitudes to first- and second-generation antipsychotic long acting injections: comparisons over 5 years. J Psychopharmacol [online 1 May 28, 2009, doi:1177/0269881109104882.
- Adams CE, Fenton MK, Quaraishi S, David. Systematic meta-analysis of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001;179; 290–9.
- Davis JM, Matalon L, Watanabe MD, Blake L. Depot antipsychotic drugs: place in therapy. Drugs 1994;47:741–3.
- Emsley R, Medori R, Koen L, Oosthuizen PP, Niehaus DJ, Rabinowitz J. Long acting injectable risperidone in the treatment of subjects with recent onset psychosis: a preliminary study. J Clin Psychopharmacol 2008;28:210–13.
- Cahn W, Rais M, Stigter FP, van Haren NEM, Caspers E, Hulshoft Pol HE, . Psychosis and brain volume changes during the first five years of schizophrenia. Eur Neuropsychopharmacol 2009;19:147–51.